VOIRX

VoiRx is a preclinical-stage biotechnology company focused on developing "chemical vision restoration" therapies for patients with advanced retinal degeneration. The company's technology is based on proprietary small-molecule photoswitches that can turn surviving retinal ganglion cells into primary light sensors, effectively bypassing dead or damaged photoreceptors. This approach aims to restore functional vision in conditions such as retinitis pigmentosa and age-related macular degeneration without the need for gene therapy or permanent electronic implants. VoiRx's platform originated from research conducted at the University of California, Berkeley, and utilizes a "molecular prosthetic" delivered via intravitreal injection. The company is currently advancing its lead candidates through preclinical studies to support future clinical trials.